Share

EORTC hosting session at ICTR-PHE 2016 in Geneva

The EORTC will host a session at ICTR-PHE 2016, the International Conference on Translational Research in Radio-Oncology – Physics for Health in Europe, from 11:00 – 12:30 on Thursday, 18 February 2016 in Session Room 2 at the Centre International de Conférences Genève in Geneva, Switzerland.

This session will be chaired by Prof Wilfried Budach of Universitaetsklinik in Dusseldorf, Germany. The session will highlight several areas of current EORTC research where the EORTC is making significant contributions towards advancing therapies for patients with cancer.

Speakers include Dr. Damien Weber of the Paul Scherrer Institute Center for Proton Therapy in Villigen, Switzerland, who will present the EORTC radiotherapy quality assurance platform.

Following him, Dr. Sofia Rivera of the Institut Gustave Roussy in Villejuif, France, will discuss Synergy of targeted agents and radiotherapy.

Dr. Rivera will be followed by Dr. Monika Hegi of the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, who will talk about Lessons from translational research in EORTC Glioma trials.

Dr. Conny Vrieling of the Clinique des Grangettes in Chêne-Bougeries, Switzerland, will close the EORTC session with a talk concerning Data from the EORTC Cancer Survivorship Task Force.

Back to news list

Related News

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023